GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

Inclusion Criteria:

- Clinical indication for coronary angiography

- Subjects already taking statin therapy, niacin or ezetimibe at screening must have
been on a stable dose for at least 4 weeks prior to screening LDL-C. Subjects not
taking lipid-regulating therapy must enter the study via a lipid stabilization period.
Subjects who are intolerant to statins must meet statin intolerance entry criteria

- Fasting LDL-C ≥ 80 mg/dL (2.07 mmol/L) with or without additional risk factors, or,
LDL-C ≥ 60 -< 80 mg/dL (1.55-2.07 mmol/L) in the presence of one major or three minor
risk factors

Subjects must meet the following criteria at the qualifying coronary catheterization
procedure:

- Evidence of coronary heart disease (at least one lesion in a native coronary artery
that has > 20% reduction in lumen diameter) or prior percutaneous intervention (PCI)

- Left main coronary artery < 50% reduction in lumen diameter by visual estimation

- Target coronary artery for IVUS must be accessible to the IVUS catheter, must not have
a > 50% reduction in lumen diameter within the target segment (and at least 40 mm in
length); cannot have undergone prior PCI or coronary artery bypass graft (CABG) and is
not a candidate for intervention over the next 18 months. It may not be a bypass
graft, bypassed vessel or culprit vessel for previous myocardial infarction (MI).

Exclusion Criteria:

- Coronary artery bypass graft surgery < 6 weeks prior to the qualifying IVUS

- New York Heart Association (NYHA) III or IV heart failure, or last known left
ventricular ejection fraction less than 30%

- Uncontrolled cardiac arrhythmia that is not controlled by medications in the 3 months
prior to randomization

- Known hemorrhagic stroke

- Uncontrolled hypertension at randomization

- Fasting Triglycerides ≥ 400 mg/dL (4.5 mmol/L) at screening

- Type 1 diabetes or poorly controlled type 2 diabetes (hemoglobin A1c [HbA1c] > 9%) at
screening.

- Moderate to severe renal dysfunction (estimated glomerular filtration rate [eGFR] < 30
ml/min/1.73m²) at screening.